Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Princeton, New Jersey 08540


Purpose:

This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.


Study summary:

Patients with Parkinson's disease with motor complications on levodopa therapy who completed the prior double-blind study 6002-INT-001 are eligible to enter into this long-term open safety study with a starting istradefylline dose of 20 or 40mg per day.


Criteria:

Inclusion Criteria: - Completion of study 6002-INT-001 - Not of childbearing potential Exclusion Criteria: - Cancer within 5 years of enrollment - ALT/AST levels > 2.5 times ULN


NCT ID:

NCT00199381


Primary Contact:

Study Director
Neil Sussman, MD
Kyowa Hakko Kirin Pharma, Inc.


Backup Contact:

N/A


Location Contact:

Princeton, New Jersey 08540
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.